Agilent Technologies Expands Microarray Service Provider Network
News Dec 20, 2006
Agilent Technologies, Inc., has announced that it has signed two new partners and recertified one more as Certified Microarray Service Providers for Agilent microarrays.
Each of these organizations received certifications after their laboratories completed training and passed a rigorous set of assessments that included proficiency in analyzing Agilent 60-mer oligo microarrays using the complete Agilent system.
"These three companies, and indeed all of our Certified Microarray Service Providers, together play a valuable role in extending our reach around the world, further enabling the power of Agilent Technologies," explains Agilent marketing manager Kevin Meldrum.
"This is an important expansion of Agilent’s Certified Service Provider program, which was founded in 2004."
"It’s gratifying to see the program catch fire in key regions around the world where important research involving microarrays is being conducted," Meldrum adds.
"We very much look forward to working with our new certified providers and to continuing our productive relationship with our newly recertified providers in the months and years to come."
Newly signed companies:
• Empire Genomics LLC, Buffalo, NY, a firm focusing on technologies to enable personalized medicine, driven by the research of Roswell Park Cancer Institute researcher Norma Nowak, Ph.D. This company can offer a wide range of products and analytical services on its array-based comparative genomics platform to characterize chromosomal abnormalities.
• Welgene Biotech Co. Ltd., Taipei City, Taiwan, focusing on microarray analysis and real-time PCR technology research. Founded in 2004, it is a subsidiary of medical device distributor Welmore Co., Ltd.
• ExonHit Therapeutics, Paris, France, with a facility in Gaithersburg, Maryland, is a company of alternative RNA splicing, the naturally occurring biological process by which a single gene can lead to several transcripts and proteins. Its SpliceArrays can make use of extensive, specific probe sets and it can provide an exhaustive monitoring of gene expression.
The system around which training is centered includes sample quality control using the Agilent 2100 Bioanalyzer, sample labeling using Agilent reagents and protocols, hybridization using SureHyb chambers, microarray analysis using the Agilent scanner and feature extraction software, and final data-analysis using the GeneSpring bioinformatics platform.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.